These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32346071)

  • 1. Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
    Gelsomino F; Tiseo M; Barbieri F; Riccardi F; Cavanna L; Frassoldati A; Delmonte A; Longo L; Dazzi C; Cinieri S; Colantonio I; Sperandi F; Lamberti G; Brocchi S; Tofani L; Boni L; Ardizzoni A
    Br J Cancer; 2020 Jul; 123(1):26-32. PubMed ID: 32346071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer.
    Tanaka H; Taima K; Morimoto T; Tanaka Y; Itoga M; Nakamura K; Hayashi A; Kumagai M; Yasugahira H; Mikuniya M; Okudera K; Takanashi S; Tasaka S
    BMC Cancer; 2017 Oct; 17(1):683. PubMed ID: 29037236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
    Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
    BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
    Baize N; Monnet I; Greillier L; Geier M; Lena H; Janicot H; Vergnenegre A; Crequit J; Lamy R; Auliac JB; Letreut J; Le Caer H; Gervais R; Dansin E; Madroszyk A; Renault PA; Le Garff G; Falchero L; Berard H; Schott R; Saulnier P; Chouaid C;
    Lancet Oncol; 2020 Sep; 21(9):1224-1233. PubMed ID: 32888454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of nab-paclitaxel plus PD-1/PD-L1 inhibitor on chemorefractory relapsed small-cell lung cancer.
    Mu F; Fan B; Li H; Qin W; Wang C; Zou B; Wang L
    Future Oncol; 2023 Jun; 19(19):1367-1378. PubMed ID: 37114967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
    Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
    Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer.
    Pasello G; Carli P; Canova F; Bonanno L; Polo V; Zago G; Urso L; Conte P; Favaretto A
    Anticancer Res; 2015 Apr; 35(4):2183-9. PubMed ID: 25862876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
    Kim YJ; Keam B; Ock CY; Song S; Kim M; Kim SH; Kim KH; Kim JS; Kim TM; Kim DW; Lee JS; Heo DS
    Lung Cancer; 2019 Oct; 136():122-128. PubMed ID: 31494530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
    Ernani V; Jahan R; Smith LM; Marr AS; Kimbrough SE; Kos ME; Tijerina J; Pivovar S; Lakshmanan I; Ketcham M; Rauth S; Mallya K; Nasser MW; Jain M; Kessinger A; Batra SK; Ganti AK
    Cancer Treat Res Commun; 2020; 22():100162. PubMed ID: 31675535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group.
    Jalal S; Bedano P; Einhorn L; Bhatia S; Ansari R; Bechar N; Koneru K; Govindan R; Wu J; Yu M; Schneider B; Hanna N
    J Thorac Oncol; 2010 Dec; 5(12):2008-11. PubMed ID: 21102263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
    Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
    JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer: A retrospective observational study.
    Oi H; Matsuda T; Kimura T; Morise M; Yamano Y; Yokoyama T; Kataoka K; Kondoh Y
    Medicine (Baltimore); 2022 Feb; 101(6):e28863. PubMed ID: 35147134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501).
    Pillai RN; Aisner J; Dahlberg SE; Rogers JS; DiPaola RS; Aisner S; Ramalingam SS; Schiller JH
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):177-83. PubMed ID: 24858462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer.
    Blomstrand H; Scheibling U; Bratthäll C; Green H; Elander NO
    BMC Cancer; 2019 Jan; 19(1):40. PubMed ID: 30621618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer.
    Heist RS; Fain J; Chinnasami B; Khan W; Molina JR; Sequist LV; Temel JS; Fidias P; Brainerd V; Leopold L; Lynch TJ
    J Thorac Oncol; 2010 Oct; 5(10):1637-43. PubMed ID: 20808253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
    Spigel DR; Jotte RM; Aix SP; Gressot L; Morgensztern D; McCleod M; Socinski MA; Daniel D; Juan-Vidal O; Mileham KF; West H; Page R; Reinmuth N; Knoble J; Chen T; Bhore R; Wolfsteiner M; Ong TJ; Gridelli C; Thomas M;
    Clin Lung Cancer; 2021 Jan; 22(1):6-15.e4. PubMed ID: 33097414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
    Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
    J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solvent-based paclitaxel or nab-paclitaxel for heavily treated relapsed/refractory small cell lung cancer: Retrospective single-institution observational study.
    Sugiyama K; Kogure Y; Torii A; Shiraishi K; Yamada A; Ishida A; Shigematsu F; Nozawa K; Niwa H; Oka S; Nakahata M; Kitagawa C; Oki M; Saka H
    Medicine (Baltimore); 2019 Mar; 98(9):e14758. PubMed ID: 30817634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
    Ciunci CA; Reibel JB; Evans TL; Mick R; Bauml JM; Aggarwal C; Marmarelis ME; Singh AP; D'Avella C; Cohen RB; Langer CJ
    Clin Lung Cancer; 2022 Jun; 23(4):e310-e316. PubMed ID: 35393247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.